James M Frates Amylyx Pharmaceuticals, Inc. (AMLX) insider trading activity

James M Frates is Chief Financial Officer of Amylyx Pharmaceuticals, Inc.. Currently has a direct ownership of 290,988 shares of AMLX, which is worth approximately $1.16 Million. The most recent transaction as insider was on Mar 31, 2025, when has been sold 10,896 shares (Common Stock) at a price of $3.47 per share, resulting in proceeds of $37,809. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 291K

24.64% 3M change

28.78% 12M change

Total Value Held $1.16 Million

JAMES M FRATES Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 31 2025	SELL Open market or private sale	$37,809 $3.47 p/Share	10,896 Reduced 3.61%	290,988 Common Stock
Mar 06 2025	BUY Grant, award, or other acquisition	-	68,420 Added 18.48%	301,884 Common Stock
Sep 12 2024	BUY Open market or private purchase	$101,199 $2.53 p/Share	40,000 Added 14.63%	233,464 Common Stock
Apr 16 2024	BUY Grant, award, or other acquisition	-	91,180 Added 28.75%	225,964 Common Stock
Mar 05 2024	SELL Open market or private sale	$33,564 $18.73 p/Share	1,792 Reduced 1.31%	134,784 Common Stock
Feb 26 2024	BUY Grant, award, or other acquisition	-	40,000 Added 20.83%	152,035 Common Stock
Jan 09 2024	SELL Open market or private sale	$44,352 $16.33 p/Share	2,716 Reduced 2.37%	112,035 Common Stock
Aug 23 2023	BUY Exercise of conversion of derivative security	$124,975 $6.88 p/Share	18,165 Added 14.59%	106,341 Common Stock
May 16 2023	SELL Open market or private sale	$886,275 $27.27 p/Share	32,500 Reduced 36.86%	55,676 Common Stock
May 16 2023	BUY Exercise of conversion of derivative security	$223,600 $6.88 p/Share	32,500 Added 26.93%	88,176 Common Stock
Mar 16 2023	SELL Open market or private sale	$1,045,199 $32.16 p/Share	32,500 Reduced 95.56%	1,509 Common Stock
Mar 16 2023	BUY Grant, award, or other acquisition	-	21,667 Added 48.32%	23,176 Common Stock
Jan 06 2023	BUY Open market or private sale	$96,857 $36.44 p/Share	2,658 Added 7.25%	34,009 Common Stock
Dec 30 2022	BUY Exercise of conversion of derivative security	$34,400 $6.88 p/Share	5,000 Added 12.0%	36,667 Common Stock
Jan 06 2022	BUY Grant, award, or other acquisition	-	31,667 Added 50.0%	31,667 Common Stock

Also insider at

SAGE

Sage Therapeutics, Inc. Healthcare

JMF

James M Frates

Chief Financial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMLX shares.

Notify only if

Value

Insider Trading

Get notified when an Amylyx Pharmaceuticals, Inc. insider buys or sells AMLX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Amylyx Pharmaceuticals, Inc.

Track Activities on AMLX

Account